BiomX Stock Set to Reverse Split on Wednesday, September 9th (NYSEAMERICAN:PHGE)

BiomX Inc. (NYSEAMERICAN:PHGE)’s stock is scheduled to reverse split on the morning of Wednesday, September 9th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, September 8th.

BiomX Price Performance

Shares of BiomX stock opened at $0.15 on Friday. The company has a current ratio of 0.24, a quick ratio of 0.24 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $3.95 million, a price-to-earnings ratio of -0.05 and a beta of 1.33. BiomX has a 1-year low of $0.12 and a 1-year high of $12.29. The firm’s 50-day moving average price is $0.20 and its two-hundred day moving average price is $1.77.

BiomX (NYSEAMERICAN:PHGE) last posted its quarterly earnings data on Wednesday, August 19th. The company reported ($0.37) earnings per share for the quarter. The firm had revenue of $0.33 million for the quarter. On average, equities analysts predict that BiomX will post -5.85 earnings per share for the current fiscal year.

Institutional Trading of BiomX

An institutional investor recently bought a new position in BiomX stock. Citadel Advisors LLC purchased a new position in shares of BiomX Inc. (NYSEAMERICAN:PHGE) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned approximately 0.61% of BiomX as of its most recent SEC filing. 40.57% of the stock is currently owned by institutional investors.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.